The Mechanism of Action and Toxicity Profile of Duvelisib (IPI-145)

Christopher Schenewerk, MD, discussed his history with alcohol abuse and how he works to break down the taboo of substance abuse among medical professionals.

Colin P.N. Dinney, MD, PhD, discussed updated analyses of the BOND-003 and CORE-001 trials in bladder cancer.

Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer diagnostics with Targeted Oncology.

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in melanoma.

David Polsky, MD, discussed a study showing ctDNA levels before melanoma treatment strongly predict recurrence and its speed, potentially guiding future therapy decisions.

Sofia Chernoff, PsyD, MSEd, discussed how cognitive behavioral therapy helps cancer patients manage emotional challenges by modifying negative thoughts and behaviors.